Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

Inclusion Criteria: * Age \>18 years old * Disease progression after treatment with the DCF regimen * Assessable target lesion(s) as defined by RECIST criteria * ECOG performance status ≤ 1 * Estimated life expectancy more than 3 months * Serum bilirubin less than 1.5 times the upper normal limit * Aspartate Aminotransferase and Alanine Aminotransferase less than 2.5 times the upper normal limit * Creatinine Clearance ≥50 ml/min * Neutrophil count more than 1.5x 109 /L * Platelet count more than 100x 109 /L * Hemoglobin more than 8g/dL * Before patient enrollment, written informed consent must be given according to Good Clinical Practice guidelines and national/local regulations. Exclusion Criteria: * Gastrointestinal bleeding * Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's discomfort * CNS metastases * Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment * Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment * Known hypersensitivity reaction to the component of the treatment * Active infection or malnutrition or bowel obstruction * Legal incapacity or limited legal capacity * Definite contraindications for the use of corticosteroids * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan * Chronic inflammation of the bowel * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment * Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent * Second primary tumor other than non-melanoma skin cancer or in situ cervical cancer